KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Retained Earnings (2016 - 2026)

TherapeuticsMD filings provide 17 years of Retained Earnings readings, the most recent being -$952.3 million for Q1 2026.

  • On a quarterly basis, Retained Earnings changed 0.02% to -$952.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$952.3 million, a 0.02% change, with the full-year FY2025 number at -$952.4 million, changed 0.06% from a year prior.
  • Retained Earnings hit -$952.3 million in Q1 2026 for TherapeuticsMD, roughly flat from -$952.4 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$939.4 million in Q4 2022 to a low of -$1.1 billion in Q1 2022.
  • Median Retained Earnings over the past 5 years was -$951.8 million (2024), compared with a mean of -$964.6 million.
  • Biggest five-year swings in Retained Earnings: dropped 19.82% in 2022 and later rose 14.31% in 2023.
  • TherapeuticsMD's Retained Earnings stood at -$939.4 million in 2022, then fell by 1.09% to -$949.6 million in 2023, then dropped by 0.23% to -$951.8 million in 2024, then dropped by 0.06% to -$952.4 million in 2025, then rose by 0.01% to -$952.3 million in 2026.
  • The last three reported values for Retained Earnings were -$952.3 million (Q1 2026), -$952.4 million (Q4 2025), and -$951.8 million (Q3 2025) per Business Quant data.